The future of molecular radiotherapy
Molecular radiotherapy (MRT) refers to treatment that delivers radiation to a tissue via the interaction of a radiopharmaceutical with a molecular receptor, although is used in a more general sense to refer to any treatment with radiotherapeutics that can take account of imaging and patient dosimetry. Probably the most well-known example of MRT is the use of I-131 NaI (radioiodine) in the treatment of both benign and malignant thyroid disease. This treatment exploits the sodium iodide sympoter (NIS), a transmembrane protein almost exclusively expressed by thyroid cells, which pumps iodine into these cells to facilitate thyroid hormone production. I-131 was first administered to patients in 1941, 80 years ago, and remains a highly effective treatment for thyroid cancer, able to cure some patients of metastatic disease.
The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.


